Rochester, Minn.-based Mayo Clinic led the study testing the product, DermaSensor, among more than 1,000 patients, according to a news release from the device’s maker. In the study, the device had a 96% sensitivity across 224 skin cancers.
The technology is indicated to further evaluate suspicious-looking lesions rather than a screening tool, according to the FDA. It can help spot melanoma and assess moles for basal cell carcinoma and squamous cell carcinoma.
“Achieving this medical milestone is a testament to the 12 years and tens of millions of dollars our company has invested in research and development to bring this powerful technology to market,” Maurice Ferre, MD, co-founder and chair of DermaSensor, said in the release.
Leave a Reply